Sector News

Sobi appoints Milan Zdravkovic SVP, Head of R&D

September 28, 2016
Life sciences

Swedish Orphan Biovitrum AB (Sobi™) today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development (R&D).

Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity.

“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Milan brings a creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”

Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. “I am looking forward to joining the team at Sobi and to advancing Sobi’s mission to develop and deliver innovative therapies to people with rare diseases,” said Milan. Milan will join Sobi on 1 November 2016.

Surce: Sobi

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.